首页> 外文期刊>Polish Archives of Internal Medicine >Diffuse large B?cell lymphoma: R?CHOP forever?

【24h】

Diffuse large B?cell lymphoma: R?CHOP forever?

机译：弥漫性大B细胞淋巴瘤：永远是R？CHOP吗？

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Polish Archives of Internal Medicine》 |2015年第10期|共2页
作者
Wies?aw W. J?drzejczak;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类内科学;
关键词

相似文献

外文文献
中文文献
专利

1. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP. [J] . Young Saing Kim, Jun Ho Ji, Young Hyeh Ko, Acta Haematologica . 2014,第3期

机译：配对分析比较利妥昔单抗-CHOP治疗的患者中富含T细胞/组织细胞的大B细胞淋巴瘤和弥漫性大B细胞淋巴瘤的结局。
2. Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases. [J] . Yoko Hashimoto, Akihiko Yokohama, Akio Saitoh, Journal of clinical and experimental hematopathology : . 2013,第3期

机译：IL-2受体α（sIL-2Rα）的可溶形式的预后重要性及其与弥散性大B细胞淋巴瘤中接受或不使用利妥昔单抗的CHOP样方案治疗的淋巴瘤细胞的IL-2Rα（CD25）表面表达的关系： 338例的回顾性分析。
3. Prognostic Importance of the Soluble Form of IL-2 Receptorα (sIL-2Rα) and its Relationship with Surface Expression of IL-2Rα (CD25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with CHOP-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases [J] . Yoko Hashimoto, Akihiko Yokohama, Akio Saitoh, Journal of clinical and experimental hematopathology : . 2013,第3期

机译：IL-2受体α（sIL-2Rα）的可溶性形式对预后的重要性及其与弥漫性大B细胞淋巴瘤淋巴瘤细胞表面表达IL-2Rα（CD25）的关系，采用或不使用利妥昔单抗的CHOP样方案治疗： 338例回顾性分析
4. CHARACTERIZING CANINE LYMPHOMA AS A POTENTIAL LARGE ANIMAL MODEL OF HUMAN DIFFUSE LARGE B-CELL LYMPHOMA [C] . Kristy Richards, Alison Motsinger-Reif, Dahlia Nielsen, Annual Conference of the Veterinary Cancer Society . 2009

机译：将犬淋巴瘤表征为人弥漫性大型B细胞淋巴瘤的潜在大型动物模型
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited non-bulky diffuse large B-cell lymphoma: a retrospective analysis [O] . Junshik Hong, Ae Jin Kim, Jin Sun Park, 2010

机译：局限性非大块弥漫性大B细胞淋巴瘤经短暂R-CHOP疗程后与利妥昔单抗-CHOP（R-CHOP）相比介入治疗放疗：回顾性分析
7. Prognostic Importance of the Soluble Form of IL-2 Receptor^^alpha; (sIL-2R^^alpha;) and its Relationship with Surface Expression of IL-2R^^alpha; (CD25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with CHOP-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases [O] . Yoko Hashimoto, Akihiko Yokohama, Akio Saitoh, 2013

机译：可溶性形式的IL-2受体^ ^α的预后重要性; （SIL-2R ^ ^ alpha;）及其与IL-2R ^ 表面表达的关系^ Alpha; （CD25）淋巴瘤在弥漫性大B细胞淋巴瘤中，用或不含rituximab处理的切碎方案治疗：338例的回顾性分析

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号